Biomarkers of Pembrolizumab Efficacy in First-Line Advanced PD-L1 ?50% Non-Small Cell Lung Cancer Treatment

L. Cabezón-Gutiérrez, S. Custodio-Cabello, Magda Palka-Kotlowska, Sílvia, María Sanchez-Luis, P. Khosravi-Shahi
{"title":"Biomarkers of Pembrolizumab Efficacy in First-Line Advanced PD-L1 ?50% Non-Small Cell Lung Cancer Treatment","authors":"L. Cabezón-Gutiérrez, S. Custodio-Cabello, Magda Palka-Kotlowska, Sílvia, María Sanchez-Luis, P. Khosravi-Shahi","doi":"10.33696/cancerimmunol.3.056","DOIUrl":null,"url":null,"abstract":"Luis Cabezón-Gutiérrez Ph.D, M.D1, Sara Custodio-Cabello Ph.D, M.D1, Magda Palka-Kotlowska M.D1, Silvia María Sanchez-Luis M.D2, Parham Khosravi-Shahi Ph.D, M.D3 1Medical Oncology, Hospital Universitario de Torrejón. Universidad Francisco de Vitoria. Madrid, Spain 2Radiotherapy Oncology, Hospital Universitario de Torrejón. Madrid, Spain 3Medical Oncology, Hospital General Universitario Gregorio Marañón. Madrid, Spain *Correspondence should be addressed to Luis Cabezón-Gutiérrez; lcabezon@torrejonsalud.com","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cancer immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33696/cancerimmunol.3.056","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Luis Cabezón-Gutiérrez Ph.D, M.D1, Sara Custodio-Cabello Ph.D, M.D1, Magda Palka-Kotlowska M.D1, Silvia María Sanchez-Luis M.D2, Parham Khosravi-Shahi Ph.D, M.D3 1Medical Oncology, Hospital Universitario de Torrejón. Universidad Francisco de Vitoria. Madrid, Spain 2Radiotherapy Oncology, Hospital Universitario de Torrejón. Madrid, Spain 3Medical Oncology, Hospital General Universitario Gregorio Marañón. Madrid, Spain *Correspondence should be addressed to Luis Cabezón-Gutiérrez; lcabezon@torrejonsalud.com
Pembrolizumab对一线晚期PD-L1疗效的生物标志物?50%非小细胞肺癌癌症治疗
Luis Cabezon-Gutierrez博士、M.D1、Sara Custodio-Cabello博士、M.D1、Magda Palka-Kotlowska M.D1、Silvia María Sanchez-Luis M.D2、Parham Khosravi-Shahi博士、M.D3 1医学肿瘤学、托雷洪大学医院。维多利亚弗朗西斯科大学。马德里,西班牙2托雷洪大学医院放射治疗肿瘤学。马德里,西班牙3医学肿瘤学,格雷戈里奥·马拉尼翁大学总医院。马德里,西班牙*应致函路易斯·卡贝松-古铁雷斯;lcabezon@torrejonsalud.com
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信